Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 15/20 | 0.76 |
| ▸ | CLK2 | P49760 | 5/20 | 0.71 |
| ▸ | CLK3 | P49761 | 5/20 | 0.71 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.71 |
| ▸ | PLK4 | O00444 | 1/20 | 0.60 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.60 |
| ▸ | AURKA | O14965 | 1/20 | 0.60 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.60 |
| ▸ | ABL1 | P00519 | 1/20 | 0.60 |
| ▸ | CDK1 | P06493 | 1/20 | 0.60 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.60 |
| ▸ | CDK4 | P11802 | 1/20 | 0.60 |
| ▸ | SRC | P12931 | 1/20 | 0.60 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.60 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.60 |
| ▸ | CCND1 | P24385 | 1/20 | 0.60 |
| ▸ | CDK2 | P24941 | 1/20 | 0.60 |
| ▸ | WEE1 | P30291 | 1/20 | 0.60 |
| ▸ | TTK | P33981 | 1/20 | 0.60 |
| ▸ | KDR | P35968 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18426821 | 0.87 | ITK (1.00) | ITKPLK4CHEK1AURKACCNB2 | |
| SCHEMBL18448378 | 0.85 | CLK2 (0.73) | ITKCLK2CLK3DYRK1APLK4 | |
| SCHEMBL18426971 | 0.84 | ITK (0.68) | ITKCLK2CLK3DYRK1A | |
| SCHEMBL29714876 | 0.84 | ITK (0.68) | ITKCLK2CLK3DYRK1A | |
| SCHEMBL18448607 | 0.84 | CLK2 (0.83) | ITKCLK2CLK3DYRK1A | |
| SCHEMBL18448626 | 0.84 | CLK2 (1.00) | ITKCLK2CLK3DYRK1A | |
| SCHEMBL18450150 | 0.83 | CLK2 (0.78) | ITKCLK2CLK3DYRK1A | |
| SCHEMBL18448953 | 0.83 | CLK2 (0.85) | ITKCLK2CLK3DYRK1A | |
| SCHEMBL18426832 | 0.82 | ITK (0.75) | ITKCLK2CLK3DYRK1APLK4 | |
| SCHEMBL18426858 | 0.82 | ITK (0.75) | ITKCLK2CLK3DYRK1APLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114728132-B | Injection system and method of use thereof | 梅里特斯英国第二有限公司 | 2025-03-25 | — | — | CN | disclosed |
| US-20240197523-A1 | MOTORIZED INJECTION SYSTEM AND METHODS OF USE | MEIRAGTX UK II LIMITED (GB) | 2024-06-20 | — | — | US | disclosed |
| EP-4196196-A1 | MOTORIZED INJECTION SYSTEM AND METHODS OF USE | Meiragtx UK II Limited (GB) | 2023-06-21 | — | — | EP | disclosed |
| CN-114728132-A | Injection system and method of use | 梅拉格特克斯治疗学股份有限公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2022036256-A1 | MOTORIZED INJECTION SYSTEM AND METHODS OF USE | BULLSEYE THERAPEUTICS, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
| WO-2021055906-A1 | INJECTION SYSTEMS AND METHODS OF THEIR USE | BULLSEYE THERAPEUTICS, INC. (US) | 2021-03-25 | — | — | WO | disclosed |
| US-10206909-B2 | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-02-19 | — | — | US | disclosed |
| US-10206909-B2 | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-02-19 | — | — | US | disclosed |
| WO-2017024004-A1 | 3-(1H-PYRROLO[2,3-B]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC. (US) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017024004-A1 | 3-(1H-PYRROLO[2,3-B]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC. (US) | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10206909-B2 | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof | WNT1, WNT3, WNT3A | ITK 2551/4885CLK2 2181/4885CLK3 2308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.